OKYO Pharma Ltd current report, Q1 FY2023

Full document

OKYO Pharma Ltd. Form 6-K Summary

Business Context and Reporting Period

OKYO Pharma Ltd., a foreign private issuer reporting on Form 20-F, furnished this Form 6-K on March 13, 2023. The filing announces the pricing of a $5.3 million offering of American depositary shares (ADSs). The filing is not a periodic financial-results report and does not provide a defined quarterly or annual reporting period.

Financial Metrics and Capitalization

  • Offering: The company announced a $5.3 million offering of ADSs.
  • Revenue, profit, cash flow, margins, debt and liquidity: The filing text does not provide clear values for these metrics.
  • Use of proceeds, offering price, number of ADSs, dilution and transaction expenses: The filing text does not provide clear details.

Material Changes Versus Prior Period

The filing text does not present comparative financial information or identify changes versus a prior comparable period. The announced ADS offering represents a financing and potential equity dilution event, but its specific impact cannot be quantified from the provided text.

Guidance, Outlook, Risks and Unusual Items

  • No financial guidance or operating outlook is provided.
  • The principal disclosed event is the pricing of the $5.3 million ADS offering.
  • Investors should consider potential dilution and the terms governing the offering, which are not fully stated in the filing text provided.
  • The announcement was furnished as Exhibit 99.1 and is stated not to be deemed filed for purposes of Section 18 of the Securities Exchange Act, or incorporated by reference into other filings, except where expressly specified.

Important Facts to Verify

  • The final offering price per ADS and the number of ADSs issued.
  • Any warrants, placement-agent fees, discounts or other transaction terms.
  • The intended use of proceeds and the expected effect on cash runway and liquidity.
  • Potential dilution to existing shareholders and any relevant anti-dilution or registration provisions.
  • The company’s latest financial statements for revenue, operating losses, cash balances, debt and cash flows.